KNG1 and angioedema: To date, although newer targeted therapies, such as intravenous plasma-derived C1 inhibitor (Cinryze) have been come out, TXA is still approved as a second-line prophylactic therapy for hereditary angiooedema [13] and further data have been published about a possible use of TXA as maintenance treatment for nonhistaminergic angioedema [14] and treatment for episodes of bradykinin-mediated angioedema induced by ACE inhibitors [15].